A growing number of women in the United Kingdom are reporting pregnancies conceived while using GLP-1 receptor agonists, a class of medications primarily prescribed for weight loss and type 2 diabetes management. These cases are prompting healthcare providers and patients to reconsider the drugs' effects on fertility and pregnancy, amid limited formal data.
One woman from Monmouthshire, currently in her third trimester, described her unexpected pregnancy after using Mounjaro, a GLP-1 injection, alongside her husband who was taking Ozempic, another drug in the same category. Both were initially surprised by the conception, as they had believed the medications might reduce fertility. Upon sharing her situation with her midwife, she was reassured that such pregnancies are reportedly common and increasingly seen in clinical settings.
Many women on online forums such as Mumsnet and Reddit have shared similar experiences, indicating that conception while on GLP-1 treatment is not an isolated incident. These accounts suggest that the medications, beyond their intended metabolic effects, might influence fertility, although the exact mechanisms remain unclear.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has acknowledged receiving multiple reports—40 in the past year—of pregnancy occurring during GLP-1 use, though experts believe the actual number is likely underreported due to patients not always informing healthcare providers or regulatory bodies.
The Monmouthshire woman, age 35, had initiated GLP-1 therapy to return to her pre-pregnancy body weight after years of managing her asthma and being classified as medically overweight based on body mass index (BMI) guidelines. Her husband started using the medication to lose weight gained through lifestyle factors associated with his profession. Both drugs are prescription-only and can be obtained through online services that require women of childbearing age to confirm they will use contraception to avoid pregnancy.
Interestingly, the woman noted changes in her menstrual cycle while on Mounjaro. Previously experiencing long, painful periods since adolescence, she found her cycles became shorter and more regular, a shift that some speculate could be related to hormonal or metabolic changes induced by GLP-1 receptor agonists.
Medical professionals caution that despite anecdotal evidence and preliminary reports, comprehensive studies are lacking to firmly establish the relationship between GLP-1 therapies and fertility outcomes. Current prescribing guidelines emphasize contraception for women of reproductive potential using these drugs due to potential risks to fetal development, but these cases underscore the complexity of balancing treatment benefits with reproductive planning.
As these medications gain popularity for weight management, especially in non-diabetic populations, monitoring pregnancy outcomes and conducting robust research will be essential to inform clinical recommendations and patient awareness.